Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q1 2026 Earnings Report

BioVie logo
$1.63 0.00 (0.00%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.62 0.00 (-0.31%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioVie EPS Results

Actual EPS
-$0.98
Consensus EPS
-$0.79
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q1 2026
Date
11/10/2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

BioVie's Q1 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q1 2026 Quarterly ReportQuarterly Report
(10-Q)

BioVie Earnings Headlines

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
September 23 at 5:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4949122-biovie-inc-bivi-discussion-of-phase-2-data-on-bezisterim-in-long-covid-and-parkinsons-with
BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
September 22 at 12:31 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biovies-ne3107-long-covid-trial-completion-what-investors-should-watch-next?utm_source=marketbeat.com&utm_medium=referral
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
September 24 at 1:00 AM  |  Paradigm Press (Ad)
Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/join-biovies-exclusive-live-investor-130000931.html
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946630-biovie-inc-bivi-discusses-topline-phase-2-address-lc-trial-data-and-the-potential-of
BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down
September 15, 2026  |  rttnews.comhttps://www.rttnews.com/3691122/biovie-s-bezisterim-shows-phase-2-signal-in-long-covid-stock-down.aspx
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. The company focuses on treatments designed to address underlying disease mechanisms, including neuroinflammation, insulin resistance and fluid accumulation associated with advanced liver disease.

BioVie’s pipeline has included NE3107, an orally administered, blood-brain barrier-penetrant small molecule being investigated for neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease. The company has described NE3107 as having potential anti-inflammatory and insulin-sensitizing properties.

BioVie has also developed BIV201, a continuous-infusion formulation of terlipressin intended to treat refractory ascites, a serious complication of liver cirrhosis. The company conducts its research and clinical-development activities primarily through collaborations and clinical programs in the United States.

View BioVie Profile
Earnings Tools